Distinguished Investigators
🇺🇸 United States
Andrei Iagaru, MD Andrew Armstrong, MD Daniel P. Petrylak, MD Geoffrey Johnson, MD Ghassan El-Haddad, MD Jeremie Calais, MD, PhD Luke T. Nordquist, MD Michael J. Morris, MD, PhD Neal Shore, MD Neeraj Agarwal, MD Oliver Sartor, MD Scott Tagawa, MD🇫🇷 France
Karim Fizazi, MD, PhD🇨🇦 Canada
Kim Chi, MD🇬🇧 United Kingdom
Professor Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD, FMedSci🇩🇪 Germany
Professor Ken Herrmann, MD🇦🇺 Australia
Professor Louise Emmett, MBChB, FRACP, FAANMS, MD
Neal Shore, MD
Neal Shore, MD, FACS Carolina Urologic Research Center Myrtle Beach, South Carolina Neal Shore graduated from Duke University and Duke University Medical School.He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the Carolina Urologic Research Center. Dr. Shore has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored more than 350 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer Advocacy Network,the APCCC Scientific Steering Committee,Maple Tree Cancer Alliance,Alessa Therapeutics, Photocure, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy, and was the co-chair of the annual AUA International Prostate Forum for 10 years. He has served/serves on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice,JUOP,Everyday Urology Oncology and World Journal of Urology.He is the Editor-in-Chief of Reviews in Urology . He is a Fellow of the American College of Surgeons and a Certified Physician Investigator.
Studies
Study Status
NCT062356099
Phase 3 Trial of Copper Cu 64 PSMA I&T PET/CT Imaging in Men with Suspected Biochemical Recurrence of Prostate Cancer (Solar-Recur)
Solar-Recur is a single-arm prospective study. Local read of the copper Cu 64 PSMA I&T PET/CT can be used to inform patient management. For the primary endpoints, PET/CT scans will be read by blinded independent reviewers.
NCT06235151
Phase 3 Trial of Copper Cu 64 PSMA I&T PET/CT Imaging in Men with Newly Diagnosed Prostate Cancer (Solar-Stage)
Solar-Stage is a single-arm prospective study. Treating physicians will not be blinded to the imaging results. Local read of the copper Cu 64 PSMA I&T PET/CT can be used to inform patient management. For the co-primary endpoints, PET/CT scans will be read by blinded independent reviewers.
NCT06056830
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
NCT05407311
64Cu-SAR-BBN Positron Emission Tomography: A Phase 2 Study of Participants With PSMA-negative Biochemical Recurrence of Prostate Cancer.
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with PSMA-negative biochemical recurrence of prostate cancer following definitive therapy.